- Home
- CXT vs IBRX Comparison
CXT vs IBRX Comparison
Compare CXT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXT
- IBRX
- Stock Information
- Founded
- CXT 1855
- IBRX 2014
- Country
- CXT United States
- IBRX United States
- Employees
- CXT N/A
- IBRX N/A
- Industry
- CXT Office Equipment/Supplies/Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CXT Industrials
- IBRX Health Care
- Exchange
- CXT Nasdaq
- IBRX Nasdaq
- Market Cap
- CXT 2.6B
- IBRX 2.4B
- IPO Year
- CXT N/A
- IBRX N/A
- Fundamental
- Price
- CXT $46.61
- IBRX $2.61
- Analyst Decision
- CXT Strong Buy
- IBRX Strong Buy
- Analyst Count
- CXT 3
- IBRX 5
- Target Price
- CXT $87.67
- IBRX $11.35
- AVG Volume (30 Days)
- CXT 426.6K
- IBRX 7.3M
- Earning Date
- CXT 05-07-2025
- IBRX 05-08-2025
- Dividend Yield
- CXT 1.46%
- IBRX N/A
- EPS Growth
- CXT N/A
- IBRX N/A
- EPS
- CXT 3.19
- IBRX N/A
- Revenue
- CXT $1,486,800,000.00
- IBRX $14,745,000.00
- Revenue This Year
- CXT $3.11
- IBRX $621.53
- Revenue Next Year
- CXT $5.35
- IBRX $163.57
- P/E Ratio
- CXT $14.59
- IBRX N/A
- Revenue Growth
- CXT 6.86
- IBRX 2270.58
- 52 Week Low
- CXT $41.54
- IBRX $2.28
- 52 Week High
- CXT $67.01
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- CXT 45.48
- IBRX 45.65
- Support Level
- CXT $42.91
- IBRX $2.35
- Resistance Level
- CXT $47.04
- IBRX $2.87
- Average True Range (ATR)
- CXT 2.21
- IBRX 0.26
- MACD
- CXT 0.45
- IBRX 0.01
- Stochastic Oscillator
- CXT 88.02
- IBRX 37.96
About CXT Crane NXT Co.
Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.